0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 01:46 ET (05:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.